The Higher Risk Of Coronary Heart Disease With Gallstone Disease
The National Institutes of Health, Bethesda, Maryland, United States says that more than three million people are suffering from gallstone disease in the United States every year. A study at the Tulane University, New Orleans, United States shows 23 percent higher risk of coronary heart disease (CHD) for patients suffering from gallstone disease.
A meta-analysis study has investigated the history of gallstone disease on 842,553 patients and 51,123 patients of coronary heart disease. The study shows 23 percent higher risk of coronary heart disease (CHD) in a patient with gallstone disease when compared to a patient without gallstone disease.
The study also found that the risk of coronary heart disease in a patient of gallstone disease is independent of other risk factors associated with coronary heart diseases such as high blood sugar (glucose) levels (diabetes), high blood pressure (or hypertension. BP), obesity. The study suggests that about three percent of men and six percent of women are with a history of gallstone.
The following are the general characteristics of a patient with a history of gallstone disease.
The authors of the study say that the health of a patient with gallstone disease should be monitored closely for the symptoms of coronary heart disease. The authors say that this study was the first study that shows an association between gallstone disease and cardiovascular disease. But this study was not showing a cause and effect relationship.
Senior author of the study was Dr. Lu Qi, professor of epidemiology, the Tulane University, New Orleans, Louisiana, United States. The study was published on August 29, 2017, in the Arteriosclerosis, Thrombosis, and Vascular Biology. Title of the article was "Gallstones and Risk of Coronary Heart Disease: Prospective Analysis of 270,000 Men and Women From 3 US Cohorts and Meta-Analysis."
The CANTOS Trial Shows That The Anti-inflammatory Drug Canakinumab (Ilaris) Can Prevent The Cardiac Events
Reducing inflammation and cholesterol levels is the current common treatment for cardiovascular diseases. But, the CANTOS clinical trial shows the new possibilities for the treatment of heart diseases.
A clinical study on the anti-inflammatory drug canakinumab, which is manufactured by Novartis AG, a Swiss pharma company, shows the prevention of cardiac events by reducing the inflammation levels. The trial was conducted on about 10,000 patients with a prior heart attack or atherosclerosis inflammatory disease.
In the trial, patients are administered with 150 mg dose of canakinumab. The trial shows about 15 percent risk reduction to major adverse cardiovascular events such as nonfatal stroke, nonfatal myocardial infarction or cardiovascular death. The trial also shows the drug canakinumab can prevent the death from lung cancer in addition to the prevention of cardiac events.
But more studies are required to find the effects of the drug canakinumab for the treatment of lung cancer. Fewer patients (or an insignificant number of participants) died with the treatment of canakinumab in the trial when compared with the patients in the placebo group.
Currently, the drug canakinumab was being marketed under brand name Ilaris for the treatment of rare and inherited diseases such as childhood form of arthritis. The drug costs about $200,000 a year in the United States. Novartis is planning to take approval of the drug canakinumab for the treatment of heart diseases in this year.
The study was published on Oct 21, 2017, in The Lancet. Title of the article was "Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial".
The Diabetes News Chronicle does not provide medical advice, diagnosis or treatment. Information in Diabetes News Chronicle is to support and not to replace medical advice given by the surgeon or physician or doctor. The published article is not a medical advice by the OWNER of the "Diabetes News Chronicle" website or by the AUTHOR of the article.
Published by Jammi Vasista, Chennai, India.